{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T19:55:59Z","timestamp":1716839759541},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.crohns.2009.05.003","type":"journal-article","created":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T04:18:00Z","timestamp":1247717880000},"page":"232-240","source":"Crossref","is-referenced-by-count":12,"title":["Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel\u2014EPACT II"],"prefix":"10.1093","volume":"3","author":[{"given":"Pierre","family":"Michetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Stelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Juillerat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Gassull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz Josef","family":"Heil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Stange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Gonvers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Pittet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John-Paul","family":"Vader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Felley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"issue":"9","key":"10.1016\/j.crohns.2009.05.003_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","article-title":"The quality of life in patients with Crohn's disease","volume":"16","author":"Cohen","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.crohns.2009.05.003_bib2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn's disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"4 Pt 2","key":"10.1016\/j.crohns.2009.05.003_bib3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.crohns.2009.05.003_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.crohns.2009.05.003_bib5","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/S0016-5085(08)82247-0","article-title":"Efficacy of oral Pentasa (R) 4\u00a0g\/day in treatment of active Crohn's disease: a meta-analysis double-blind, placebo-controlled trials","volume":"120","author":"Hanauer","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.crohns.2009.05.003_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.crohns.2009.05.003_bib7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.crohns.2009.05.003_bib8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","article-title":"The effectiveness of budesonide therapy for Crohn's disease","volume":"16","author":"Kane","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.crohns.2009.05.003_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.crohns.2009.05.003_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.crohns.2009.05.003_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.crohns.2009.05.003_bib12","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1111\/j.1572-0241.2000.03363.x","article-title":"Infliximab in Crohn's disease: first anniversary clinical experience","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.crohns.2009.05.003_bib13","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","article-title":"Clinical experience with infliximab therapy in 100 patients with Crohn's disease.[comment]","volume":"95","author":"Farrell","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"9317","key":"10.1016\/j.crohns.2009.05.003_bib14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.crohns.2009.05.003_bib15","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","article-title":"An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease","volume":"99","author":"Sandborn","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.crohns.2009.05.003_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","article-title":"Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab","volume":"100","author":"Papadakis","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.crohns.2009.05.003_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2036.2006.03232.x","article-title":"Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial","volume":"25","author":"Hinojosa","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.crohns.2009.05.003_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.crohns.2009.05.003_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"issue":"11\u201312","key":"10.1016\/j.crohns.2009.05.003_bib20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study","volume":"20","author":"Winter","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.crohns.2009.05.003_bib21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.crohns.2009.05.003_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.crohns.2009.05.003_bib23","first-page":"A21","article-title":"Certoluzimab pegol administered subcutaneously is effective in anti-TNF naive patients and in patients previously treated with infliximab","volume":"55","author":"Colombel","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.05.003_bib24","first-page":"CD006097","article-title":"Natalizumab for induction of remission in Crohn's disease","volume":"1","author":"Macdonald","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.crohns.2009.05.003_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/0148607195019005356","article-title":"How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials","volume":"19","author":"Fernandez-Banares","year":"1995","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"4","key":"10.1016\/j.crohns.2009.05.003_bib26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0016-5085(95)90203-1","article-title":"Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease","volume":"108","author":"Griffiths","year":"1995","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.crohns.2009.05.003_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/00365529609004877","article-title":"Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis","volume":"31","author":"Messori","year":"1996","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.crohns.2009.05.003_bib28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.crohns.2009.05.003_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0016-5085(93)90709-L","article-title":"Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. [comment]","volume":"105","author":"Ewe","year":"1993","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.crohns.2009.05.003_bib30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"issue":"7737","key":"10.1016\/j.crohns.2009.05.003_bib31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(71)90598-8","article-title":"Controlled trial of azathioprine in Crohn's disease","volume":"2","author":"Rhodes","year":"1971","journal-title":"Lancet"},{"issue":"7731","key":"10.1016\/j.crohns.2009.05.003_bib32","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0140-6736(71)90268-6","article-title":"Controlled trial of azathioprine in Crohn's disease","volume":"2","author":"Willoughby","year":"1971","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.crohns.2009.05.003_bib33","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0016-5085(74)80166-6","article-title":"Treatment of Crohn's disease with azathioprine: a controlled evaluation","volume":"66","author":"Klein","year":"1974","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.crohns.2009.05.003_bib34","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","article-title":"Azathioprine and 6-Mercaptopurine in Crohn Disease\u2014a metaanalysis","volume":"123","author":"Pearson","year":"1995","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.crohns.2009.05.003_bib35","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"27","key":"10.1016\/j.crohns.2009.05.003_bib36","first-page":"1724","article-title":"Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Arora","year":"1999","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"10.1016\/j.crohns.2009.05.003_bib37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.[comment]","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.crohns.2009.05.003_bib38","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1002\/ibd.3780070505","article-title":"Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience","volume":"7","author":"Cohen","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.crohns.2009.05.003_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00054725-200203000-00002","article-title":"Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital","volume":"8","author":"Hommes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.crohns.2009.05.003_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.crohns.2009.05.003_bib41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"3 Suppl","key":"10.1016\/j.crohns.2009.05.003_bib42","first-page":"S92","article-title":"Surgical management of patients with inflammatory bowel disease: consensus and controverse","volume":"27","author":"Panis","year":"2003","journal-title":"Gastroenterol Clin Biol"},{"issue":"1","key":"10.1016\/j.crohns.2009.05.003_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000083866","article-title":"Therapy of mild to moderate luminal Crohn's disease","volume":"71","author":"Michetti","year":"2005","journal-title":"Digestion"},{"issue":"1","key":"10.1016\/j.crohns.2009.05.003_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000083867","article-title":"Severe and steroid-resistant Crohn's disease","volume":"71","author":"Michetti","year":"2005","journal-title":"Digestion"},{"issue":"26","key":"10.1016\/j.crohns.2009.05.003_bib45","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJM199806253382612","article-title":"What is appropriate care?","volume":"338","author":"Naylor","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.crohns.2009.05.003_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000095505","article-title":"Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach-EPACT","volume":"73","author":"Vader","year":"2006","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.crohns.2009.05.003_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000111021","article-title":"EPACT II: project and methods","volume":"76","author":"Juillerat","year":"2007","journal-title":"Digestion"},{"issue":"1","key":"10.1016\/j.crohns.2009.05.003_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1017\/S0266462300002774","article-title":"A method for the detailed assessment of the appropriateness of medical technologies","volume":"2","author":"Brook","year":"1986","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.crohns.2009.05.003_bib49","first-page":"CD002913","article-title":"Budesonide for maintenance of remission in Crohn's disease","author":"Benchimol","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"10.1016\/j.crohns.2009.05.003_bib50","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1136\/gut.2005.081950b","article-title":"European evidence based consensus on the diagnosis and management of Crohn's disease: current management","volume":"55","author":"Travis","year":"2006","journal-title":"Gut"},{"issue":"suppl II","key":"10.1016\/j.crohns.2009.05.003_bib51","first-page":"A1","article-title":"Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathiprine to azathioprine to patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"57","author":"Colombel","year":"2008","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.crohns.2009.05.003_bib52","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.crohns.2009.05.003_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"issue":"9613","key":"10.1016\/j.crohns.2009.05.003_bib54","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/3\/4\/232\/1275326\/3-4-232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T10:18:42Z","timestamp":1558433922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2009.05.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1873994609000580"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2009.05.003","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}